Recently Featured

Supreme Court Tariff Ruling Upholds Trump’s Authority to Target Pharma

February 25, 2026
In a significant legal development, the Supreme Court has upheld President Donald Trump’s authority to impose tariffs on pharmaceutical imports, despite previous setbacks in his tariff strategies. This ruling solidifies the administration’s ability to leverage tariffs as a tool for influencing drug pricing and trade negotiations, a move that could reshape the landscape of pharmaceutical…

Altesa Biosciences Secures $75 Million in Series B Funding to Advance COPD Therapy

February 25, 2026
Altesa Biosciences, co-led by former Assistant US Health Secretary Brett Giroir, has successfully raised $75 million in a Series B funding round aimed at advancing its anti-rhinoviral therapy for chronic obstructive pulmonary disease (COPD) into mid-stage clinical trials. This significant financial backing underscores the growing interest and investment in innovative treatments targeting respiratory diseases, particularly…

Candel Prices $100M Offering, Signs $100M Royalty Deal; Calquence Label Expands

February 24, 2026
Candel Therapeutics has priced a $100 million public offering, aiming to enhance its aglatimagene besadenovec program, an innovative oncolytic virus-based therapy designed for cancer treatment. This strategic move comes as the company seeks to bolster its financial resources to advance its clinical pipeline and expand its market presence. The funds raised will play a crucial…

Daiichi Sankyo Appoints John Tsai as New R&D Leader Following Ken Takeshita’s Departure

February 24, 2026
John Tsai, a seasoned executive with extensive experience as a chief medical officer at Novartis and Amgen, has been appointed to lead Daiichi Sankyo’s global research and development (R&D) initiatives, effective April 1. This leadership transition comes as Ken Takeshita steps down from his role, marking a significant shift in the company’s strategic direction. Takeshita’s…

Ongoing Cases